Zoetis Inc. Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions
Zoetis Inc. (ZTS) reported Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions of $3.00 million for the 3-month period ending 2017-04-02, per its 10-K filed 2020-02-13.
Discontinued › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions · last filed 2020-02-13
- Zoetis Inc. unrecognized tax benefits, decrease resulting from current period tax positions for the quarter ending 2017-04-02 was $3.00M.
- Zoetis Inc. unrecognized tax benefits, decrease resulting from current period tax positions for fiscal 2016 was $2.00M.
- Zoetis Inc. unrecognized tax benefits, decrease resulting from current period tax positions for fiscal 2013 was $0.00.
- Zoetis Inc. unrecognized tax benefits, decrease resulting from current period tax positions for fiscal 2012 was $0.00.
- Zoetis Inc. unrecognized tax benefits, decrease resulting from current period tax positions for fiscal 2011 was $0.00.
| Period end | Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions 3 month | Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions 12 month |
|---|---|---|
| 2017-04-02 | $3.00M 10-K · filed 2020-02-13 | |
| 2016-12-31 | $2.00M 10-K · filed 2019-02-14 | |
| 2013-12-31 | $0.00 10-K · filed 2014-03-26 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-26 | |
| 2011-12-31 | $0.00 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |